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Catalysis offers efficient means to produce enantiopure
products. Traditionally, enzymatic and homogeneous catalysis
have evolved independently to afford mild, robust, active, and
highly selective catalysts.[1,2] Both systems are often consid-
ered complementary in terms of substrate and reaction scope,
operating conditions, enantioselectivity mechanism, reaction
medium, etc. For the optimization of activity and selectivity,
directed-evolution methodologies (combined with an effi-
cient selection or screening tool) outperform combinatorial
ligand libraries.[3–13] With the hope of alleviating some of the
inherent limitations of both enzymatic and organometallic
catalysis, two approaches have recently witnessed a revival:
1) organocatalysis[14–19] and 2) artificial metalloenzymes based
on either covalent[20,21] or supramolecular anchoring[22] of a
catalytic moiety in a macromolecular host.[23–30]
Inspired by the early works of Whitesides and Wilson,[22]
we recently reported artificial metalloenzymes based on the
biotin–avidin technology.[31–35] Herein, we report our efforts to
produce substrate-specific and S-selective artificial metal-
loenzymes based on the biotin–avidin technology for the
hydrogenation of a-acetamidodehydroamino acids.
The starting point for the chemogenetic-optimization
procedure presented herein is the identification of [Rh(cod)-
(biot–1)]+S112G Sav (cod= 1,5-cyclooctadiene, biot=
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biotin, Sav= streptavidin, Scheme 1) as the best ligand–
protein combination for the enantioselective reduction
of a-acetamidoacrylic acid (up to 96% ee in favor of (R)-
acetamidoalanine (N-AcAla)).[32,33] These observations
prompted us to perform saturation mutagenesis at
position 112 of WT-Sav. The resultant 20 proteins were
combined with the biotinylated catalyst precursors
[Rh(biot-spacer-P2)cod]BF4 (P= diphenylphosphine
donor; Scheme 1) to afford 360 artificial metalloen-
zymes. To gain broader insight into the substrate
specificity, the catalytic runs were performed on both
a-acetamidoacrylic acid and a-acetamidocinnamic acid
simultaneously (both 50 equiv, Scheme 1). Control
experiments established that the selectivity and conver-
sion are identical to those obtained with a single
substrate (i.e. no autoinduction).[6,36] The detailed exper-
imental procedure is provided in the Supporting Infor-
mation.
The results of the chemogenetic-screening experi-
ments with both substrates are summarized in Figure 1
by using a fingerprint display for each substrate–protein–
ligand combination.[37] The selectivity is color coded:
pink for S-selective and green for R-selective ligand–
protein combinations. The intensity of the color reflects
the percentage of conversion.[38] Both substrates are
displayed as two hypotenuse-sharing triangles (HyShaTri)
for each ligand–protein matrix element. This convenient
display allows rapid identification of interesting ligand–
protein combinations. Selected results are collated in
Table 1 and a summary, including all catalytic runs (as
well as multiple reproduction of selected experiments), is
provided in the Supporting Information.
Analysis of the results that are displayed graphically in
Figure 1 reveals several noteworthy general features:
1) Most ligand–protein combinations yield distinctively
different results for both substrates. This trend is
reflected by the differences in color (selectivity) and/or
intensity (activity) for two HyShaTri (Figure 1). In
general, enantioselectivity for N-AcPhe was higher
than for N-AcAla; however, the reverse trend was
observed for conversion as the smaller substrates
systematically display higher yields.
2) The chemical optimization brings more diversity than
the genetic counterpart. This is best illustrated through
the comparison of line vectors (i.e. chemical optimiza-
tion) with column vectors (i.e. genetic optimization).
The line vector S112P yields reduction products with
both R and S configurations in respectable ee values for
N-AcPhe (Table 1, entries 5 and 8).
3) Overall, the ligand scaffold 1 outperformed the ligand
scaffold 2 both in terms of enantioselectivity and con-
version. The best spacer–ligand combinations are biot–1
(which yields R products, Table 1, entries 1–5) and biot–
4meta–1, in combination with cationic amino acid residues
in position 112 (which yields S products, Table 1,
entries 6–9). We speculated that the cationic side chains
interact through ionic hydrogen bonds with the carboxyl-
ate functionality of the substrate, thus favoring coordina-
tion of one of the prochiral faces of the substrate.
4) The most pronounced differences in substrate selectivity
(in terms of conversion) are observed with biot–31–2 in
combination with aromatic residues in position 112
(Table 1, entries 10–12).
5) For the biot-1 vector, the lowest conversions were
obtained with mutants that had a potentially coordinating
amino acid side chain in position 112 and included S112C
(Table 1, entry 3), S112D, S112H, and S112M (to a lesser
extent S112E and S112Y as well, Figure 1). We speculated
Scheme 1. Operating conditions used for the chemogenetic optimization of artificial
hydrogenases in the reduction of a-acetamidoacrylic acid and a-acetamidocinnamic
acid (50 equiv of each with respect to the ligand). MES buffer solution is composed of
4-morpholineethanesulfonic acid that is pH adjusted with sodium hydroxide.
Figure 1. Fingerprint display of the results for the chemogenetic optimization for
the reduction of a-acetamidoacrylic acid (top triangle) and a-acetamidocinnamic
acid (bottom triangle) in the presence of 18 biotinylated ligands and 20 streptavidin
isoforms obtained by saturation mutagenesis at position 112.
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that these Lewis basic side chains coordinate to the
rhodium center, thus interfering with the catalytic cycle.
6) Introduction of a glutamine in position 112 yields R-
selective artificial metalloenzymes when combined with
biot-34-2 (92% ee (R), Table 1, entry 13).
This study thus demonstrates the potential of saturation
mutagenesis at position 112 coupled with chemical optimiza-
tion to yield both R and S reduction products as well as
substrate-specific artificial metalloenzymes. Although gen-
eral trends in enantioselectivity are mostly dictated by the
biot–spacer–ligand scaffold (chemical optimization), satura-
tion mutagenesis (genetic optimization) provides the critical
second-coordination-sphere interactions between the host
protein and the prochiral substrate. It is precisely such crucial
weak interactions between a catalyst and its substrate that
distinguish enzymatic from homogeneous systems.[41]
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Entry Ligand Protein ee
N-AcPhe[1]
ee
N-AcAla[2]
Conv.
N-AcPhe
Conv.
N-AcAla
1 biot–1 WT Sav 93(R) 94(R) 84 quant.[3]
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11 biot–31–2 S112W 33(S) 59(S) 8 96
12 biot–31–2 S112Y 42(S) 55(S) 10 quant.[3]
13 biot–34–2 S112Q 92(R) 87(R) 77 quant.[3]
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3
mented in an Excel macro: RGB1= [100(y*x)/100]*2.55;
RGB2= [100(z*x)/100]*2.55; RGB3= 0.5*(RGB1+RGB2).
[39] To solubilize both substrates, MES buffer solution (0.1m, pH 5.5)
was used. Compared with the buffer solution traditionally used
for a-acetamidoacrylic acid (0.1m acetate, pH 4.0), slightly lower
conversions (up to 5%) and lower enantioselectivities (up to
3%) were occasionally encountered. For the sake of coher-
ence, all results presented herein are based on the dual substrate
screening which must be performed in 0.1m MES (pH 5.5). This
is because of the low solubility of a-acetamidocinnamic acid in
0.1m acetate buffer at pH 4.0. The results reported previously for
N-AcAla (96% ee (R) with the biot–1–S112G) can be attained
only with an 0.1m acetate buffer (pH 4.0).[32,33]
[40] W. S. Knowles, Acc. Chem. Res. 1983, 16, 106.
[41] For a recent example of the exploitation of second-coordination-
sphere interactions in organocatalysis, see: T. P. Yoon, E. N.
Jacobsen, Angew. Chem. 2005, 117, 470; Angew. Chem. Int. Ed.
2005, 44, 466.
4
